1369389-66-1

Basic information

• Product Name: [6-(4-(4-[2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonylamino]-tetrahydro-pyran-4-carbonyl)-piperazin-1-yl)-6-oxo-hexyl]-trimethyl-ammonium trifluoroacetate salt
• Synonyms: [6-(4-(4-[2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonylamino]-tetrahydro-pyran-4-carbonyl)-piperazin-1-yl)-6-oxo-hexyl]-trimethyl-ammonium trifluoroacetate salt
• CAS NO: 1369389-66-1
• Molecular Weight: 876.822
• Mol File: 1369389-66-1.mol

Chemical Properties

• CAS DataBase Reference: [6-(4-(4-[2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonylamino]-tetrahydro-pyran-4-carbonyl)-piperazin-1-yl)-6-oxo-hexyl]-trimethyl-ammonium trifluoroacetate salt(CAS DataBase Reference)
• NIST Chemistry Reference: [6-(4-(4-[2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonylamino]-tetrahydro-pyran-4-carbonyl)-piperazin-1-yl)-6-oxo-hexyl]-trimethyl-ammonium trifluoroacetate salt(1369389-66-1)
• EPA Substance Registry System: [6-(4-(4-[2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonylamino]-tetrahydro-pyran-4-carbonyl)-piperazin-1-yl)-6-oxo-hexyl]-trimethyl-ammonium trifluoroacetate salt(1369389-66-1)

Safety Data

• Hazardous Substances Data: 1369389-66-1(Hazardous Substances Data)

Upstream product

• 883969-09-3 tert-butyl 4-(4-[2,4-dichloro-3-(2,4-dimethylquinolin-8-yloxymethyl)benzenesulfonylamino]tetrahydropyran-4-ylcarbonyl)piperazine-1-carboxylate 
• 884049-25-6 2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-N-[4-(piperazine-1-carbonyl)-tetrahydro-pyran-4-yl]-benzenesufonamide 
• 68409-45-0 6-trimethylammonio-caproic acid 
• 76-05-1 trifluoroacetic acid 
• 883969-08-2 4-[2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonylamino]-tetrahydropyran-4-carboxylic acid 

Relevant articles and documents

Design and synthesis of novel sulfonamide-containing bradykinin hB 2 receptor antagonists. Synthesis and structure-relationships of α,α-tetrahydropyranylglycine

A series of α,α-cycloalkylglycine sulfonamide compounds of general formula 1 has previously been identified by our group as selective human B2(hB2) receptor antagonists. Here we report the in vitro and in vivo BK antagonist activity